CD19 and diffuse large B-cell lymphoma: Clinical trials of CAR-T targeting CD19 in adults with relapsed or refractory diffuse large B-cell lymphoma have achieved high rates of durable responses, demonstrating the enormous potential of CART-T therapy in the treatment of haematologic malignancies [46].